The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac

Postgraduate Medicine

Volumn 124, Issue 1, 2012, Pages 117-123

  Manvelian, Garen ^a   Daniels, Stephen ^b   Gibofsky, Allan ^c,d  

^a Iroko Pharmaceuticals   (United States)

^b Premier Research   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Diclofenac; Nanotechnology; NSAID

Indexed keywords

DICLOFENAC; NANOPARTICLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NANOPHARMACEUTICS; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FORMULATION; GASTROINTESTINAL DISEASE; OPEN STUDY; TREATMENT DURATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NANOPARTICLES;

EID: 84858987371     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.01.2524     Document Type: Article

References (26)

1. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693-11697.
2. Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1):19-34.
3. Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80(4B):18-23.
4. Indomethacin [package insert]. Edison, NJ: Heritage Pharmaceuticals, Inc; July 2010.
5. Naproxen [package insert]. Ingelheim, Germany: Boehringer Ingleheim, Roxane Laboratories; February 2010.
6. Voltaren [package insert]. Basel, Switzerland: Novartis Pharmaceuticals Corp; February 2011.
7. Gluszko P, Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? Pol Arch Med Wewn. 2009;119(4): 231-235.
8. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther. 2005;7(suppl 4):S14-S22.
9. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320-326.
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.p df. Accessed July 20, 2011.
11. Bakshi R, Frenkel G, Dietlein G, Meurer-Witt B, Schneider B, Sinterhauf U. A placebo-controlled comparative evaluation of diclofenac dispersible versus ibuprofen in postoperative pain after third molar surgery. J Clin Pharmacol. 1994;34(3):225-230.
12. Bamber MJ, Tweedie IE, Breeze C, Williams NE. Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Eur J Anaesthesiol. 1997;14:421-427.
13. Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study. Clin Pharmacol Ther. 1999;66(6):625-635.
14. Hersh EV, Levin LM, Adamson D, et al. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 2004;26(8):1215-1227.
15. Matthews RW, Scully CM, Levers BG. The efficacy of diclofenac sodium (Voltarol) with and without paracetamol in the control of post-surgical dental pain. Br Dent J. 1984;157(10):357-359.
16. Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig. 2007;27:163-195.
17. Cataflam [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; July 2005.
18. Hinz B, Chevts J, Renner B, et al. Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59(1):80-84.
19. Macia MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther. 1995;33(6):333-339.
20. Riad LE, Sawchuk RJ, McAlary MM, Chan KK. Effect of food on the multiple-peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am J Ther. 1995;2(4):237-242.
21. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther. 2000;38(11):546-551.
22. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481.
23. US Food and Drug Administration. Public health advisory-FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforP atientsandProviders/ucm150314.htm. 2005. Accessed September 15, 2011.
24. US Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361 .htm. 2004. Accessed September 15, 2011.
25. FlectorPatch [package insert] Bristol, TN: King Pharmaceuticals, Inc; February 2011.
26. VoltarenGel [package insert]. Basel, Switzerland: Novartis; October 2009.